Cost-Effectiveness of Pembrolizumab Plus Trastuzumab and Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-Line Treatment of HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma in China.

ABSTRACT:

Objective

This study aimed to evaluate the cost-effectiveness of pembrolizumab in combination with trastuzumab and chemotherapy (PEM + TRAS + Chemo) as a first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma from the perspective of the Chinese healthcare system.

Methods

Clinical data from the KEYNOTE-811 trial were used to develop a partitioned survival model for HER2-positive gastric or GEJ adenocarcinoma. The model estimated quality-adjusted life years (QALYs), life years (LYs), and total lifetime costs. The primary outcome was the Incremental Cost-Effectiveness Ratio (ICER), reflecting the cost per additional QALY. Only direct medical costs were considered, with drug prices sourced from the China Drug Biddi

SUBMITTER: Liang Y 

PROVIDER: S-EPMC12631738 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature